Niemann Pick C1 Like Protein 1 (NPC1L1) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 38 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Niemann Pick C1 Like Protein 1 (NPC1L1) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Niemann Pick C1 Like Protein 1 (NPC1L1) - Pipeline Review, H1 2016', provides in depth analysis on Niemann Pick C1 Like Protein 1 (NPC1L1) targeted pipeline therapeutics. 

The report provides comprehensive information on the Niemann Pick C1 Like Protein 1 (NPC1L1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Niemann Pick C1 Like Protein 1 (NPC1L1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Niemann Pick C1 Like Protein 1 (NPC1L1)
- The report reviews Niemann Pick C1 Like Protein 1 (NPC1L1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Niemann Pick C1 Like Protein 1 (NPC1L1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Niemann Pick C1 Like Protein 1 (NPC1L1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Niemann Pick C1 Like Protein 1 (NPC1L1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Niemann Pick C1 Like Protein 1 (NPC1L1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Niemann Pick C1 Like Protein 1 (NPC1L1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Niemann Pick C1 Like Protein 1 (NPC1L1) Overview 6
Therapeutics Development 7
Niemann Pick C1 Like Protein 1 (NPC1L1) - Products under Development by Stage of Development 7
Niemann Pick C1 Like Protein 1 (NPC1L1) - Products under Development by Therapy Area 8
Niemann Pick C1 Like Protein 1 (NPC1L1) - Products under Development by Indication 9
Niemann Pick C1 Like Protein 1 (NPC1L1) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Niemann Pick C1 Like Protein 1 (NPC1L1) - Products under Development by Companies 12
Niemann Pick C1 Like Protein 1 (NPC1L1) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 17
Niemann Pick C1 Like Protein 1 (NPC1L1) - Companies Involved in Therapeutics Development 18
Alvogen Korea Co., Ltd. 18
Chong Kun Dang Pharmaceutical Corp. 19
CJ HealthCare Corp. 20
Esperion Therapeutics, Inc. 21
Kotobuki Pharmaceutical Co., Ltd. 22
Merck & Co., Inc. 23
Zhejiang Hisun Pharmaceutical Co., Ltd. 24
Niemann Pick C1 Like Protein 1 (NPC1L1) - Drug Profiles 25
(atorvastatin calcium + ezetimibe) - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
(atorvastatin calcium + ezetimibe) - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
(bempedoic acid + ezetimibe) - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
(ezetimibe + rosuvastatin calcium) - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
(ezetimibe + rosuvastatin calcium) - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
(ezetimibe + rosuvastatin calcium) - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
HS-25 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
KT-6971 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Niemann Pick C1 Like Protein 1 (NPC1L1) - Dormant Projects 33
Niemann Pick C1 Like Protein 1 (NPC1L1) - Featured News & Press Releases 34
Feb 15, 2016: Merck Receives Complete Response Letter from the U.S. FDA for ZETIA (ezetimibe) 34
Jan 14, 2014: Merck Voluntarily Recalls All Lots of LIPTRUZET in the United States From Wholesalers Due to Packaging Defects 35
May 03, 2013: Merck Gets FDA Approval For Liptruzeta For Treatment Of Primary Or Mixed Hyperlipidemia 35
Jan 02, 2013: Merck Announces FDA Acknowledgement Of Resubmission Of New Drug Application For Ezetimibe/Atorvastatin Tablets 35
Apr 04, 2012: Frontage Successfully Files IND To Launch US Statin Study 36
Nov 03, 2009: FDA Turns Down Merck's Application For Combo Cholesterol Pill Involving Lipitor 36
Mar 27, 2007: Merck And Schering To Develop Zetia/Lipitor Combo As Focus On Reducing Bad Cholesterol Returns 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 37
Disclaimer 38

List of Tables

Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Assessment by Monotherapy/Combination Products, H1 2016 14
Number of Products by Stage and Mechanism of Action, H1 2016 15
Number of Products by Stage and Route of Administration, H1 2016 16
Number of Products by Stage and Molecule Type, H1 2016 17
Pipeline by Alvogen Korea Co., Ltd., H1 2016 18
Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 19
Pipeline by CJ HealthCare Corp., H1 2016 20
Pipeline by Esperion Therapeutics, Inc., H1 2016 21
Pipeline by Kotobuki Pharmaceutical Co., Ltd., H1 2016 22
Pipeline by Merck & Co., Inc., H1 2016 23
Pipeline by Zhejiang Hisun Pharmaceutical Co., Ltd., H1 2016 24
Dormant Projects, H1 2016 33